November 19, 2016 9:05am

 

… As the iShares Nasdaq Biotechnology (IBB) fell -1.32%

In relation to the upside versus the downside; the gap widens and closes in two days followed by the reverse

 

 

I answer one question; in which company should investors put, keep and commit their money!

Pre-open indication’s tally:  3 hits (BSTG, BTX and KOOL) and 1 miss (AST)

 

Lose an advantage or be a subscriber!  Today’s results have implications to Monday's sector activity.  

 

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

 

 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

 

U.S. equities closed slightly lower on Friday, led by health care, as investors digested Federal Reserve officials' remarks on monetary policy and falling oil prices.

The NASDAQ closed DOWN -12.46 or -0.23% to 5,321.51 and the DOW closed also closed DOWN -35.89 or -0.19% to 18,867.93.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was positive with an A/DL of 21/18 and 4 flats;                      
  • The mid-day stayed positive with an A/DL of 22/20 and 1 flat;
  • The closing bell was positive with A/DL of 24/17 and 2 flats;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCG&RT) sector opened positive, slipped negative at the mid-day and closed positive.

  • From this morning’s investor’s letter, “After the see-saw of advance/decline lines, who wants to be too long over a weekend? Forget a glass half full or half empty, I want a glass.”

All three indexes were on track for weekly gains, with the NASDAQ outperforming, up more than 1.8% for the week so far.

  • All three indexes posted weekly gains, with the NASDAQ outperforming, up more than 1.7% for the week. The small-cap Russell 2000 registered its longest win streak since a 12-session advance that lasted from May 20 to June 5, 2003.

The CBOE Volatility index (VIX), widely considered the best gauge of fear in the market, traded slightly lower, near 13.2.

 

As I had stated, “Vulnerability is today’s buzz word!  “Our” universe is always in some sort of sentiment pain, as the sharply up and painfully down syndrome seems never leaves.”

 

At the close …

  • Gainers included Kite Pharma (KITE +$1.24), Bellicum (BLCM +0.49), Applied Genetic Technologies (AGTC +$0.45), bluebird bio (BLUE +$0.35) and StemCells (STEM +$0.20) contributed the most gains;
  • The biggest losers of the session were Spark Therapeutics (ONCE -$2.49), Regenxbio (RGBX -$1.05), Juno Therapeutics (JUNO -0.68) Cellectis SA (CLLS -0.39) and ReNeuron (RENE.L -$0.25)

 

The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded lower, near 13.5.

 

The iShares Russell 2000 (IWM) indicated a positive pre- open of +0.18% and closed UP +0.53% while the iShares NASDAQ Biotechnology (IBB) indicate a pre-open positive of +0.11% and closed DOWN -1.32%.

 

 

The downside trend reflects a pricing trend range of:

  • Friday’s decliners ranged from -0.31% <ONVO>to -12.34% <NWBO>in 17 equities
  • Thursday’s decliners ranged from -0.78% <JUNO> to-21.28% <STEM> in 15 equities;
  • Wednesday’s decliners ranged from -0.42% <STML> to -14.93% <IMUC> in 26 equities;
  • Tuesday’s decliners ranged from -0.02% <OPXA> to -9.52% <RENE.L> in 27 equities;
  • Monday’s decliners ranged from –o.21% <CLLS> to -6.48% <FATE> in 17 equities;
  • Last Friday’s decliners ranged from -0.61% <CYTX> to -10.79% <IMUC> in 10 equities;

 

The upside shows a pricing trend range of:

  • Friday’s gainers ranged from +0.21% <MESO> to +21.82% <OPXA> in 24 equities;
  • Thursday’s gainers ranged from +0.14% <IMUC> to +12.50% in 28 equities;
  • Wednesday’s gainers ranged from +0.46% <OSIR> to +31.78% <STEM> to in 13 equities;
  • Tuesday’s gainers ranged from +0.58% <AXGN> to +11.11% <CLBS> in 13 equities
  • Monday’s gainers ranged from +0.59% <ATHX> to +15.62% <CAPR> <> in 23 equities;
  • Last Friday’s gainers ranged from +0.53% <VTGN> to +36.28% <FATE>in 31 equities;

 

Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers. The shifting correlation of the number of equites inclining versus the decliners hasn’t abated!

  • Friday’s 24 gainers compared to Thursday’s 28 following Wednesday’s 13 post Tuesday’s 13 followed Monday’s 23 after last Friday’s 31 …

 

  • Friday’s 17 decliners compared to Thursday’s 15 following Wednesday’s 26 after Tuesday’s 27 decliners post Monday’s 17 compared to last Friday’s 10...

 

 

Pre-open indication’s tally:  3 hits (BSTG, BTX and KOOL) and 1 miss (AST)

  • Asterias Biotherapeutics (NYSEMKT: AST) closed UP +$0.11 – miss;
  • BioTime (NYSEMKT: BTX) closed UP +$0.05 – hit;
  • Biostage (BSTG) closed DOWN -$0.03 – hit;
  • Cesca Therapeutics (KOOL) closed DOWN -$0.18 – hit;

 

 

Percentage decliners:

  • Northwest Bio (NWBO) -12.34%;
  • ReNeuron (RENE.L) -9.52% after Thursday’s +10.53%;
  • ImmunoCellular (NYSEMKT: IMUC) -6.56%
  • Cesca Therapeutics (KOOL) -5.31% after Thursday’s +7.62%;
  • International Stem Cell (ISCO) -5.29%;

 

 

Percentage advancers:

  • Opexa (OPXA) +21.82% after Thursday’s -6.76% after Wednesday’s +5.34%;
  • StemCells (STEM) +18.02% after Thursday’s -21.28% after Wednesday’s +31.78%;
  • Fibrocell (FCSC) +13.42%;
  • Athersys (ATHX) +8.38%;
  • Applied Genetic Technologies (AGTC) +4.69%

 

 

Flat:                                                                                                      

  • BioLife Solutions (BLFS) at $1.55;
  • Vericel (VCEL) at $2.40;

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Friday traded near 13.2;

·         Thursday traded near 13.5;

·         Wednesday traded near 13.9;

·         Tuesday traded near 13.4;

·         Monday traded near 14.9;

·         Last Friday traded near 14.17 – a 3.87% decrease;

 

                                                                                                             

                                                                                                                            

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.